Tuesday’s Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology
Vanda Pharmaceuticals, Prosensa, and Clovis Oncology could all loom large in health care headlines this morning. Here’s why.
Surprising MS Drug Approval: Time to Buy?
The EU has issued a preliminary approval for Translarn, the Duchenne muscular dystrophy drug developed by PTC Therapeutics.
Is Prosensa Holding About to Soar?
Clinical-stage biotechs developing treatments for Duchenne muscular dystrophy have recently won a handful of political battles that have helped their drugs move forward on the regulatory front. Could Prosena be the next company to benefit from this change in political sentiment?
3 Stocks That Soared Stupendously Last Week
These 3 health-care stocks blew away the market this week. Here's how they did it.
Small Advances for Healthcare Stocks; PTC Therapeutics Rallies After Duchenne Muscular Dystrophy Dru
Small Advances for Healthcare Stocks; PTC Therapeutics Rallies After Duchenne Muscular Dystrophy Drug Approved